Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 05/15/2026 | PUT | $800.00 | 1,016 | +940 | +1,236.84% |
| 05/01/2026 | PUT | $830.00 | 940 | +930 | +9,300.00% |
| 05/15/2026 | PUT | $840.00 | 978 | +917 | +1,503.28% |
| 05/15/2026 | CALL | $1,080.00 | 1,014 | +872 | +614.08% |
| 05/15/2026 | CALL | $1,000.00 | 1,000 | +849 | +562.25% |
| 03/20/2026 | CALL | $935.00 | 854 | +640 | +299.07% |
| 03/20/2026 | PUT | $1,080.00 | 40 | -152 | -79.17% |
| 03/20/2026 | PUT | $1,030.00 | 90 | -163 | -64.43% |
| 03/20/2026 | PUT | $940.00 | 1,151 | -240 | -17.25% |
| 03/20/2026 | PUT | $1,050.00 | 103 | -298 | -74.31% |
| 03/20/2026 | PUT | $1,040.00 | 40 | -299 | -88.20% |
| 03/20/2026 | PUT | $1,060.00 | 78 | -480 | -86.02% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.74% | 26M | 11.45B |
| Vanguard 500 Index Fund | 1.92% | 18.23M | 8.03B |
| Vanguard/Primecap Fund | 1.56% | 14.85M | 6.54B |
| Fidelity 500 Index Fund | 0.91% | 8.65M | 3.81B |
| SPDR S&P 500 ETF Trust | 0.90% | 8.54M | 3.76B |
| Vanguard Specialized-Health Care Fund | 0.80% | 7.64M | 3.37B |
| iShares Core S&P 500 ETF | 0.74% | 7.04M | 3.1B |
| Washington Mutual Investors Fund | 0.73% | 6.95M | 3.06B |
| Growth Fund Of America Inc | 0.71% | 6.7M | 2.95B |
| Select Sector SPDR Fund-Health Care | 0.67% | 6.41M | 2.82B |
Amphista Therapeutics appoints Louise Modis Ph.D. as CEO and Patrick Kelly M.D. as CMO and provides a business update as the Company prepares to file IND application for AMX-883
03/18 08:00 am
GlobeNewswire Inc.
Read moreBetter Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics
03/17 08:30 pm
The Motley Fool
Read moreEli Lilly Analyst Flags Overhyped Obesity Drug Expectations
03/17 12:57 pm
Benzinga
Read moreNovo Nordisk A/S Investigated by the Portnoy Law Firm
03/17 09:00 am
GlobeNewswire Inc.
Read moreDefensive Sectors: Are Utilities, Staples, and Health Care Signaling Trouble?
03/17 02:44 am
Investing.com
Read moreShould You Avoid Pfizer? Here's the Key Risk to Watch
03/17 01:15 am
The Motley Fool
Read moreEli Lilly's Eczema Drug Shows Strong Skin Clearance In Phase 3 Pediatric Trial
03/16 08:43 am
Benzinga
Read moreAmgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report
03/16 07:19 am
Benzinga
Read moreBIO-Europe Spring® 2026: Partnering Momentum Builds as Global Biopharma Leaders Set Course for Lisbon
03/16 06:00 am
GlobeNewswire Inc.
Read moreIs Eli Lilly's Weight Loss Empire in Trouble?
03/13 06:30 pm
The Motley Fool
Read moreThe Real Reason Eli Lilly Is Pouring $3 Billion Into China
03/13 01:21 pm
Investing.com
Read moreUsing Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
03/12 02:04 pm
Benzinga
Read moreProQR Announces Year End 2025 Operating and Financial Results
03/12 07:00 am
GlobeNewswire Inc.
Read moreEli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline
03/12 06:46 am
Benzinga
Read moreForget Oral Wegovy: This Weight Loss Drug Could Be an Even Bigger Winner
03/11 02:30 pm
The Motley Fool
Read more2 Healthcare Stocks That Are Too Cheap to Ignore
03/10 12:23 pm
The Motley Fool
Read moreRoche's Breast Cancer Drug Falls Short In Phase 3 Study
03/09 08:09 am
Benzinga
Read moreBetter Weight Loss Stock: Novo Nordisk Vs. Amgen
03/08 02:30 pm
The Motley Fool
Read more1 Dividend Stock to Buy Hand Over Fist and 1 to Avoid
03/08 01:30 pm
The Motley Fool
Read moreWhere Will Eli Lilly Stock Be in 10 Years?
03/07 12:15 pm
The Motley Fool
Read moreDown but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?
03/06 07:05 pm
The Motley Fool
Read moreChina Clears Weight-Loss Shot As Pfizer Enters Crowded Market
03/06 09:14 am
Benzinga
Read moreRoche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly
03/06 07:47 am
Benzinga
Read moreNovo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors
03/05 05:05 pm
The Motley Fool
Read moreGLP-1 Receptor Agonist (Trulicity, Wegovy, Ozempic, Mounjaro) Market Trends Analysis Report 2026
03/05 11:58 am
GlobeNewswire Inc.
Read moreGLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - Clinical Trials Exploring GLP-1 Role in NAFLD and NASH Unlock Future Opportunities
03/04 06:48 am
GlobeNewswire Inc.
Read more2 Top Growth Stocks to Buy in the First Half of 2026
03/03 08:15 pm
The Motley Fool
Read moreShould You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?
03/03 04:14 pm
The Motley Fool
Read moreBuying This 1 Pharmaceutical Stock Today Could Make You a Multimillionaire Retiree
03/02 02:15 pm
The Motley Fool
Read moreAntibiotics Market - 4.07% CAGR Forecast for 2026-2031 as Antimicrobial Innovation Strengthens Demand, Says Mordor Intelligence
03/02 05:59 am
GlobeNewswire Inc.
Read moreThe New Magnificent Stocks to Own in 2026
02/27 01:06 pm
Investing.com
Read moreNvidia Hit by Profit Taking but $300 Target Still in Sight
02/26 04:37 pm
Investing.com
Read morePatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race
02/26 02:35 pm
GlobeNewswire Inc.
Read moreHims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore
02/26 08:17 am
The Motley Fool
Read moreThe Next Magnificent 7? 4 Large Caps Gaining Momentum
02/26 03:05 am
Investing.com
Read moreEli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know.
02/25 03:15 pm
The Motley Fool
Read moreOzempic Price War - Novo Nordisk Slashes Prices By 50%
02/25 10:13 am
Benzinga
Read more5 Stocks With 20%+ EPS Growth and Strong Balance Sheets
02/25 03:53 am
Investing.com
Read moreCould Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush?
02/25 01:30 am
The Motley Fool
Read moreNovo Nordisk's China Obesity Drug Cuts Nearly One-Fifth Of Body Weight
02/24 07:00 am
Benzinga
Read moreGot $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.
02/23 09:30 pm
The Motley Fool
Read moreStock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short
02/23 06:21 pm
The Motley Fool
Read more1 Reason I'd Buy Veeva Systems Stock and Never Sell
02/23 05:37 pm
The Motley Fool
Read moreViking Therapeutics Stock Gains Amid Obesity Drug Buzz
02/23 03:29 pm
Benzinga
Read moreNovo Nordisk Trades at 11x Earnings as GLP-1 Reset Tests Long-Term Thesis
02/23 02:22 pm
Investing.com
Read moreNovo Nordisk's Loss Is Eli Lilly's Gain
02/23 12:42 pm
Benzinga
Read moreNovo Nordisk Tumbles in 'Worst Case Scenario': Next-Gen Weight Loss Drug Underperforms
02/23 12:35 pm
Benzinga
Read moreEli Lilly: The Weight‑Loss and Diabetes Powerhouse I'd Hold Through Any Market Crash
02/23 11:30 am
The Motley Fool
Read more1 Reason I'm Seriously Considering Novo Nordisk as a Buy‑and‑Never‑Sell Obesity Stock
02/23 08:18 am
The Motley Fool
Read more